New Mesothelioma Immunotherapy Clinical Trial at Baylor University
A new clinical trial at Baylor University’s Mesothelioma Treatment Center is looking at the effectiveness of using immunotherapy before surgery.
Category: Immunotherapy
FDA Approves Keytruda For A New Type of Cancer
The U.S. Food and Drug Administration (FDA) has approved the drug Keytruda for patients with head and neck squamous cell carcinoma (HNSCC).
Immunotherapy Trial for Mesothelioma Shows Early Promise
The immunotherapy drug avelumab showed promising results in a recent phase I clinical trial for malignant mesothelioma, raising hopes as a future second-line therapy. The clinical trial included 53 patients with pleural or peritoneal mesothelioma. It was part of the JAVELIN development program for avelumab, a series of clinical studies testing the drug on about…
The post Immunotherapy Trial for Mesothelioma Shows Early Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
FDA-Approved Keytruda Treatment Could Help Mesothelioma Patients
Recently, the FDA approved Merck immunotherapy drug Keytruda for treatment in non-small cell lung cancer and is bringing hope to mesothelioma patients.
New Mesothelioma Treatment Receives FDA Orphan Drug Designation
A new drug has been granted Orphan Drug Status by the US FDA as a potentially safe and effective treatment for mesothelioma cancer.
Can Opdivo Drug Be Good News for Mesothelioma Patients?
Expanded approved use of new lung cancer drug Opdivo could give malignant pleural mesothelioma patients hope.
Results from Immunotherapy Clinical Trial Give Hope for Treatment of Mesothelioma
Clinical Trial Explores How Immunotherapy May Help Treat Mesothelioma